Oncology Institute Inc (TOI) - Total Liabilities
Based on the latest financial reports, Oncology Institute Inc (TOI) has total liabilities worth $184.51 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TOI long-term investment intensity to see how much of total assets are deployed in long-term investments.
Oncology Institute Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Oncology Institute Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Oncology Institute Inc balance sheet assets.
Oncology Institute Inc Competitors by Total Liabilities
The table below lists competitors of Oncology Institute Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BlackRock MIT II
NYSE:BLE
|
USA | $368.24 Million |
|
Autolus Therapeutics Ltd
NASDAQ:AUTL
|
USA | $418.24 Million |
|
Electrosteel Castings Limited
NSE:ELECTCAST
|
India | Rs40.16 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥88.79 Million |
|
Jiangxi Huawu Brake Co Ltd
SHE:300095
|
China | CN¥1.36 Billion |
|
Lem Holding SA
SW:LEHN
|
Switzerland | CHF194.44 Million |
|
Penyao Environmental Protection Co Ltd Class A
SHE:300664
|
China | CN¥3.34 Billion |
|
Shandong Homey Aquatic Development Co Ltd
SHG:600467
|
China | CN¥3.34 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Oncology Institute Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Oncology Institute Inc (TOI) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -11.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oncology Institute Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oncology Institute Inc (2019–2025)
The table below shows the annual total liabilities of Oncology Institute Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $180.38 Million | +6.65% |
| 2024-12-31 | $169.13 Million | +11.11% |
| 2023-12-31 | $152.22 Million | +9.91% |
| 2022-12-31 | $138.49 Million | +39.49% |
| 2021-12-31 | $99.28 Million | +164.13% |
| 2020-12-31 | $37.59 Million | +117.29% |
| 2019-12-31 | $17.30 Million | -- |
About Oncology Institute Inc
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as edu… Read more